batoprotafib

Batoprotafib (TNO155) is an orally bioavailable, potent, and selective allosteric inhibitor of the protein tyrosine phosphatase SHP2 (Src homology region 2 domain-containing phosphatase-2), which is encoded by the *PTPN11* gene. Developed by Novartis, batoprotafib functions by binding to the inactive, closed conformation of SHP2, thereby preventing its activation and subsequent signaling through the RAS/MAPK pathway. This pathway is a critical mediator of cellular growth and survival and is frequently dysregulated in various malignancies, particularly those driven by receptor tyrosine kinase (RTK), NF1, or KRAS mutations. Batoprotafib is primarily being investigated for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer, and head and neck squamous cell carcinoma, often as a monotherapy or in combination with other targeted agents such as KRAS G12C inhibitors.

Brand names

TNO155TNO-155TNO 155

Other names

batoprotafib